Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Marketing
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
AZ and Merck were the first to grab an FDA approval for Lynparza, and, despite growing competition, the drug is set to remain top in the PARP space.
Ben Adams
Apr 24, 2024 8:23am
To boost production of T1D candidates, Vertex jumps to TreeFrog
Apr 24, 2024 7:25am
Sponsored
MAIC Methodology Matters: Comparing BRUKINSA vs Acalabrutinib in R/R CLL
Apr 1, 2024 8:00am
Orphan drug market to reach $270B by 2028: Evaluate
Apr 24, 2024 12:01am
Sponsored
The biopharma “brain drain”: Finding talent to fuel innovation
Jan 26, 2024 8:00am
Day One pressures Novartis with FDA nod for novel RAF inhibitor
Apr 23, 2024 10:13pm